Andrographis (Expanded) for Respiratory Health

Research suggests that Andrographis paniculata may offer some benefit for respiratory health in the context of mild COVID-19, though the evidence remains preliminary and inconsistent. The available studies include two retrospective cohort studies and one small randomized controlled trial, with two of the three reporting lower rates of pneumonia progression among patients who received andrographis extract compared to those who did not, while a third retrospective study found no statistically significant protective effect. The randomized trial did find a significant reduction in CRP, a marker of inflammation, among treated participants, though it was underpowered to draw firm conclusions on other outcomes. Taken together, the body of evidence is too limited and mixed to support confident claims about efficacy, and researchers across all three studies have called for larger, well-controlled trials before drawing definitive conclusions.